"Botanical blends" is a retail shelf category, not a plant, a formula, or a legal classification. In practice it names the group of kratom-free botanical supplements that moved into shelf space previously held by kratom-derivative products — most visibly Cat's Claw, kava, kanna and functional mushrooms. The phrase describes where a product sits in a store, not what is inside it, and that distinction is the whole reason this article exists.
We are a distributor and retailer. We do not manufacture, formulate or private-label anything — we carry other companies' brands, and we screen them before we stock them. So this is a buyer's-eye account of a category we buy from and resell, not a pitch for something we developed.
Quick answer: what the term covers
| Subset | Plant | Characteristic compound class | Federal status as of 30 July 2026 |
|---|---|---|---|
| Cat's Claw products | Uncaria tomentosa (Rubiaceae) | Oxindole and indole alkaloids | Not scheduled; not named in the 2026 DEA action |
| Kava | Piper methysticum (Piperaceae) | Kavalactones — not alkaloids at all | Not controlled under the Controlled Substances Act; FDA treats it as a lawful dietary ingredient that carries a safety communication |
| Kanna | Sceletium tortuosum (Aizoaceae) | Mesembrine-type alkaloids | Not federally scheduled; its dietary-ingredient basis is genuinely unsettled |
| Functional mushrooms | Lion's mane, reishi, cordyceps, chaga, turkey tail, maitake | Beta-glucans and other polysaccharides | Ordinary dietary ingredients; no scheduling issue |
Four different plant families. Four unrelated chemistries. One shelf. That is the honest shape of the category, and any store telling you these products are variations on a theme is telling you something about its merchandising, not about botany.
Where the term came from, and why it appeared in 2026
The phrase was in circulation before this year, but it hardened into a category label after 1 July 2026, when the Drug Enforcement Administration filed two Notices of Intent to temporarily schedule certain kratom-derived compounds under 21 U.S.C. 811(h). Both published in the Federal Register on 6 July 2026. FR Doc 2026-13580 covers 7-hydroxymitragynine above a threshold of 0.050% w/w, or 1.00 mg per article. FR Doc 2026-13581 covers mitragynine pseudoindoxyl, MGM-15 (dihydro-7-hydroxymitragynine) and MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine), with no threshold at all — any detectable amount.
The orders take effect on or after 5 August 2026, on the date the order itself publishes. They run two years and can be extended by one while permanent scheduling is considered. A temporary scheduling order of this kind is not subject to judicial review. There is no grace period and no sell-through provision: retail sale of a Schedule I substance to the public is not permitted, and a holder without the relevant registration has to surrender stock rather than move it. We walk through the mechanics in our explainer on the scheduling action and the arithmetic of the threshold in the 7-OH threshold breakdown.
Retailers with shelf space to fill did not wait for the effective date. Within weeks, "botanical blends" became the sign over the space — a deliberately broad term that let stores reorganise inventory without making a claim about any specific plant.
What the term does not tell you
This is the part most of the category leaves out. "Botanical blends" is not a specification. It carries no requirement about species, dose, extraction method, testing, or manufacturing standard. A product can carry the label and be:
- a single-ingredient extract with a per-lot certificate from an ISO/IEC 17025-accredited laboratory, or
- an undisclosed proprietary blend with no batch number, no lot code and no published analysis at all.
Both are equally entitled to the phrase. So the term is useful for navigating a store and close to useless for evaluating a product. Every meaningful question — what species, what part of the plant, how much per serving, tested for what by whom — has to be asked separately.
A second limit worth stating flatly: "kratom-free" is a claim about absence, and absence claims are only as good as the analyte list behind them. A certificate can only report on the compounds it looked for. We cover what that actually means in our guide to reading a certificate of analysis, and it is the single most important thing to understand about lab documents in this category.
The four subsets, and what separates them
Cat's Claw (Uncaria tomentosa)
A woody Amazonian vine, family Rubiaceae — the same family as coffee. It is a different plant from kratom (Mitragyna speciosa) and is not named anywhere in the 2026 scheduling action. Commercial material is the inner bark, usually sold as an extract in flavoured tablets, sachets or shots. If you want the botany rather than the retail framing, start with our guide to what Cat's Claw actually is, compare the categories side by side in Cat's Claw vs kratom vs 7-OH, and see the current lineup in the Cat's Claw collection.
Here is where candour costs us something. Two of the supplier certificates on our own shelf report Total Alkaloids 0.00 and mitraphylline non-detect — meaning no Uncaria marker alkaloid was found in those specific batches. Some brands' own listings describe their products as containing a proprietary indole alkaloid from the Cat's Claw plant; that is the brand's description of its own product, and we report it as the brand's claim rather than repeating it in our voice. We are not going to assert a composition the certificates in our possession do not support.
Kava (Piper methysticum)
A Pacific pepper-family shrub. Its characteristic constituents are kavalactones, which are not alkaloids — a useful reminder that the plants in this category have almost nothing chemically in common. Kava is not controlled under the Controlled Substances Act, and FDA treats it as a lawful dietary ingredient that is the subject of a safety communication rather than one the agency has concluded is unlawful.
The status is settled; the conditions are not casual. Kava carries a well-documented liver-safety discussion and an industry-standard label warning that responsible sellers use whether or not any regulation compels it. There is also a sharp regulatory split between kava sold as a sealed dietary supplement and kava sold as a food or beverage ingredient. We treat that split as a hard sourcing rule.
Kanna (Sceletium tortuosum)
A South African succulent in the ice-plant family. Its alkaloids are mesembrine-type — structurally unrelated to anything in kratom or Uncaria. Kanna is not federally scheduled, and we can find no FDA enforcement action against it. The open question is different and more technical: whether it qualifies as a lawful dietary ingredient at all. Only one New Dietary Ingredient notification for a kanna article appears in the public record, and the agency has not posted its response letter. Published accounts disagree about how that notification resolved.
That is an unresolved legal-basis question, and we say so rather than papering over it. There is also a documented potency problem in the ingredient: a substantial share of kanna-labelled products has been found to contain no kanna or only trace amounts.
Functional mushrooms
Lion's mane, reishi, cordyceps, chaga, turkey tail and maitake are ordinary dietary ingredients with no scheduling question attached. The risk here is commercial rather than legal: mycelium-on-grain products sold at fruiting-body prices can be substantially starch, which is why the discriminating test is a certificate that quantifies beta-glucan and alpha-glucan separately. Most brands do not publish that. The ones worth carrying do.
What we exclude from the category, and why
A shelf definition is only meaningful if something fails it. Two things do, for us.
Amanita muscaria. It is being pitched hard into the "functional mushroom" channel, but FDA has affirmatively concluded that it is a new dietary ingredient that does not meet the safety standard at FFDCA 402(f)(1)(B), and the agency has acted publicly against products containing it. Some states also restrict it under hallucinogenic-plant statutes. It is not a functional mushroom in any sense we recognise.
Blue lotus (Nymphaea caerulea). No New Dietary Ingredient notification has ever been filed for it, it is not generally recognised as safe, and forensic testing of seized products sold as blue lotus has repeatedly found synthetic cannabinoids in the material. A kratom-derivative test panel would not detect that adulterant class. We decline the category outright.
How to evaluate anything on this shelf
- Find the Latin binomial. Common names are shared across unrelated plants. The species name is the only checkable identity claim on a label.
- Find the batch number, then match it to a certificate. A COA that is not tied to the lot in your hand is marketing.
- Read the analyte list before you read the results. A page of non-detects proves nothing if the compound you care about was never on the panel.
- Check who ran the test. Independent and accredited is not the same as in-house, and individual line items on an otherwise-accredited certificate can fall outside the laboratory's accredited scope.
- Check whether purity was tested at all. Alkaloid-only certificates with heavy metals and microbials marked "not tested" are common in this category.
Everything we hold is posted on our COA page, including the gaps. If you want the chemistry vocabulary behind those documents, our explainer on indole alkaloids unpacks the phrase that appears on more labels in this category than any other.
Frequently Asked Questions
Is "botanical blends" a legally defined term?
No. It has no definition in federal regulation and no required standard behind it. It is a retail category name. Legal status attaches to specific ingredients and specific formulations, not to the phrase on the shelf tag.
Does "botanical blends" mean the product contains multiple botanicals?
Not necessarily. Plenty of products in the category are single-ingredient. The word "blend" here describes the shelf, and on individual labels a "proprietary blend" is usually a formatting choice that lets a manufacturer disclose a total weight without disclosing per-ingredient amounts.
Are the products you carry kratom-free?
The supplier certificates we hold support three statements and no more: no kratom, no mitragynine, no 7-OH, at the reporting limits the laboratory used. Those same panels do not test for mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B, so we do not describe anything we carry as cleared of a compound nobody looked for. Commissioning independent testing that closes that gap is work in front of us, and we would rather say so than write around it.
Is Cat's Claw affected by the 2026 DEA scheduling action?
Uncaria tomentosa is a different plant from Mitragyna speciosa and is not named in either Federal Register notice. What matters legally is the actual composition of a finished product, not the plant named on the front of the package — which is why the analyte coverage of the certificate matters more than the marketing.
Which subset should a first-time buyer start with?
We are not going to answer that, because it would require claims about effects that we have no basis to make. What we will say is that documentation quality varies enormously between subsets, and functional mushrooms currently have the clearest testing standards of the four.
These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Consult a qualified healthcare professional before use. Legality of any given product depends on its specific formulation and on applicable federal, state, and local law. Nothing here is legal advice.